IHIzolda Heydenrych

Izolda Heydenrych

*This is an algorithmically generated author record based on publicly available information.

Izolda Heydenrych has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    International Expert Consensus on Integrated Skincare Active Ingredients for Pretreatment and Posttreatment Use With Medical Aesthetic Procedures to Enhance Skin Benefits

    by Peter Bjerring, Zoe D. Draelos, Sabrina G. Fabi, Greg J. Goodman, Kwun Cheung Hau, Ariel Haus, Izolda Heydenrych, Jihee Kim, Liang‐Chen Lin, Karim Sayed, et al.

    Background: Integrated skincare (ISC) combines dermocosmetics with medical aesthetic procedures to improve outcomes. However, guidance on selecting appropriate active ingredients across different procedure types and phases remains limited. Aims: To provide international guidance on appropriate ISC actives for use with aesthetic procedures. Methods: In a simplified Delphi study, 14 experts evaluated 44 actives for use across four procedure categories (ablative energy‐based, non‐ablative energy‐based, non‐energy‐based procedures with or without skin barrier disruption) at four time points (pretreatment, peri‐treatment, aftercare, and follow‐up ≥ 1 week post‐procedure). The panelists also ranked their top five preferred actives for each procedure category and time point. Results: Ceramides, cholesterol, hyaluronic acid, niacinamide, and peptides were deemed appropriate across all procedure categories and all time points. Azelaic acid, benzoyl peroxide, cysteamine, glycolic acid, hydroquinone, lactic acid, retinoids, and salicylic acid were identified as unsuitable for use on treatment day. Ceramides and hyaluronic acid were highly ranked for pre‐treatment, peri‐treatment and aftercare, while retinoids and ferulic acid were highly ranked for pretreatment and followup. Vitamin C was ranked in the top 5 across all procedure categories and time points, except at pretreatment for non‐energy‐based without skin barrier damage. Conclusions: Safety and tolerability are primary considerations when selecting ISC actives. Ingredients with higher irritation potential, such as retinoids and acids, should be avoided during the healing phase (on treatment day and during short‐term aftercare) due to risk of irritation, as well as post‐inflammatory hyperpigmentation in skin of color.


  • Open Access

    Dermocosmetics in Acne Vulgaris: South African Consensus Recommendations With a Focus on Skin of Color

    by Willem I. Visser, Susanna M. Kannenberg, Alice Prevost, Nokubonga Khoza, Lushen Pillay, Kimberley J. Wiid, Izolda R. Heydenrych

    Background: Acne vulgaris is one of the most common dermatological disorders worldwide, affecting both adolescents and adults. It frequently leads to significant psychosocial and physical sequelae, including acne‐induced hyperpigmentation and scarring. Beyond pharmaceutical therapies, dermocosmetics—topical formulations enriched with active ingredients in cosmetically elegant vehicles—have emerged as essential partners in acne management. They optimize clinical outcomes by supporting skin barrier repair, reducing irritation associated with conventional treatments, and targeting key pathogenic pathways in acne. However, no region‐specific guidance exists to inform the effective use of dermocosmetics in South African patients, particularly those with skin of color. Aims: To develop expert consensus recommendations for the use of dermocosmetics in acne vulgaris management within the South African context. Methods: This consensus was developed through structured expert meetings and a targeted literature review of current international and local evidence. The panel synthesized clinical experience and research findings to identify key principles for selecting and integrating dermocosmetics into acne treatment regimens. Results: The consensus highlights the multifaceted role of dermocosmetics in addressing core acne pathogenic factors, supporting epidermal barrier function, mitigating treatment‐related adverse effects, and managing acne‐induced hyperpigmentation in skin of color. Practical recommendations are provided for their use as adjunctive therapy, monotherapy in mild cases, and maintenance therapy to sustain remission. Conclusion: This South African consensus provides a practical, evidence‐informed framework for incorporating dermocosmetics into acne management, with particular attention to the needs of patients with skin of color. Adoption of these recommendations may enhance treatment outcomes, adherence, and patient satisfaction across diverse skin types.


  • Open Access

    The 10-Point Plan 2021: Updated Concepts for Improved Procedural Safety During Facial Filler Treatments [Corrigendum]

    by Izolda Heydenrych, Koenraad De Boulle, Krishan Mohan Kapoor, Dario Bertossi

    Corrigendum for the article The 10-Point Plan 2021: Updated Concepts for Improved Procedural Safety During Facial Filler Treatments


  • Open Access

    The 10-Point Plan 2021: Updated Concepts for Improved Procedural Safety During Facial Filler Treatments

    by Izolda Heydenrych, Koenraad De Boulle, Krishan Mohan Kapoor, Dario Bertossi

    Dermal filler treatments require constant reassessment for improving and safeguarding the rapidly evolving aesthetic field. Suboptimal injection technique, patient selection and product knowledge have touted a concerning increase in filler complications, with new challenges such as the COVID-19 pandemic leading to new paradigms in the understanding, prevention, diagnosis and treatment of complications. The updated 10-point plan has been developed to curtail complications through consideration of causative factors, categorized as patient, product, and procedure-related. Patient-related factors include a preprocedural consultation with careful elucidation of skin conditions (acne, rosacea, dermatitis), systemic disease (allergies, autoimmune disease, underlying bacterial and viral disease (herpes simplex virus, COVID-19 infection), medications (antineoplastic drugs, recreational drugs) and previous cosmetic procedures (including fillers and energy-based devices). Patient assessment should include standardized photography and also evaluate the role of social media, ethnicity, gender, generational, and LGBTQ+ needs. Specified informed consent for both adverse events and their treatment is essential due to the increase in vascular complications, including the risk of blindness. Product-related factors include the powerful advantage of reversibility when using hyaluronic acid (HA) products. Product characteristics such as molecular weight and filler degradation should be understood. Product layering over late or minimally degradable fillers is still inadvisable due to the initial filler being teased into reactivity. Procedural factors such as consistent photographic documentation, procedural planning, aseptic non-touch technique (ANTT), knowledge of topographical anatomy and angiosomes, and technical dexterity including pinch anatomy and needle skills are of pivotal importance. The final section is dedicated to algorithms and checklists for managing and treating complications such as allergic hypersensitivity reactions, vascular events, infection, edema and late-onset adverse events (LOAEs). The updated 10-point plan is a methodical strategy aimed at further minimising the risk of dermal filler complications.


  • Open Access

    Considerations for the Use of Minimally Invasive Aesthetic Procedures for Facial Remodeling in Transgender Individuals

    by Koenraad De Boulle, Nobutaka Furuyama, Izolda Heydenrych, Terrence Keaney, Alexander Rivkin, Vincent Wong, Michael Silberberg

    There is increasing demand among transgender individuals for minimally invasive aesthetic procedures, such as injectable facial fillers and neurotoxins, for facial remodeling and transformation. These procedures may increase transgender individuals’ satisfaction with their appearance and allow them to more effectively harmonize their physical appearance with their perception of self. There is currently a lack of information in the medical literature regarding guidelines for the use of these products in transgender patients. In this report, the authors provide experience-based treatment considerations and recommendations for use of minimally invasive facial aesthetic procedures in transgender patients, including case studies illustrating the use of these procedures for both male-to-female and female-to-male transitioning patients. This report highlights the success of minimally invasive methods for assisting transgender patients in achieving their facial remodeling goals. Clinicians play an integral role in the transitioning process for transgender patients, and facial transformation is a key element of this process. When conducted with sensitivity and attention to individual patient goals at varying stages of transition, facial procedures can be of great benefit in enhancing patients’ self-perception and overall quality of life.


  • Open Access

    The Treatment of Facial Asymmetry with Botulinum Toxin: Current Concepts, Guidelines, and Future Trends

    by Izolda Heydenrych

    This article will describe facial asymmetry secondary to facial nerve paralysis (FNP), and review current concepts, guidelines, and future trends. Despite the increasing use of botulinum toxin (BoNTA) in treating FNP, ideal dosage, timing, and additional therapies are not unequivocally established. Facial asymmetry significantly impacts quality of life (QOL) by strongly affecting self-perception and social interactions; injectables may mediate great clinical improvement. This article provides practical guidelines for the use of BoNTA and provides schemes for accurate assessment and documentation. A systematic, stepwise approach is recommended with methodical assessment, meticulous placement, conservative dosage, and careful follow-up. Future trends include the potential use of newly developed toxins, muscle modification with fillers, improved imaging techniques, and targeted QOL studies. Hopefully, a growing number of aesthetic injectors may become technically proficient and join multidisciplinary teams for managing FNP.


  • Open Access

    Expert Consensus on Injection Technique and Area-Specific Recommendations for the Hyaluronic Acid Dermal Filler VYC-12L to Treat Fine Cutaneous Lines

    by Patricia Ogilvie, Jesper Thulesen, Christophe Leys, Dimitris Sykianakis, Jonquille Chantrey, Marva Safa, Vitor Figueiredo, Izolda Heydenrych, Maurizio Cavallini, Elin Kringen Langeland, et al.

    Background: VYC-12L is a hyaluronic acid (HA) injectable gel designed to treat fine cutaneous lines and improve skin quality attributes such as hydration and elasticity. Objective: Expert consensus was sought on VYC-12L injection technique and primary treatment target areas. Methods: A multinational group of aesthetic medicine clinicians (n = 128) attended product training and each identified ∼ 10 patients for VYC-12L. After treating their first and last patients, the clinicians completed a survey on preferred injection methodology/technique, including injection angle, volume, and spacing. An expert panel (n = 12) discussed survey results and their clinical experiences to obtain consensus on VYC-12L technique and appropriate treatment areas. Results: Recommendations included micro-depot injections of VYC-12L into the deep dermis with a 32G ½ inch needle inserted at < 45º to the skin, spaced 0.5‒1.0 cm apart, with 0.01‒0.05 mL volume per injection (full-face total volume: ∼ 2 mL). Recommended primary treatment areas were the malar, perioral, neck, and décolletage regions. Injection techniques for different treatment areas/demographic characteristics were similar, with some variability in treatment approach. Patient selection criteria, pre- and post-treatment guidelines, and managing patient expectations are important components of treatment. Conclusion: These consensus recommendations may assist clinicians in optimizing the treatment of fine lines with VYC-12L.


  • Top Cited Papers
    Open Access

    A 10-point plan for avoiding hyaluronic acid dermal filler-related complications during facial aesthetic procedures and algorithms for management

    by Izolda Heydenrych, Krishan M Kapoor, Koenraad De Boulle, G. J. Goodman, Arthur Swift, Narendra Kumar, Eqram Rahman

    The recent rapid growth in dermal filler use, in conjunction with inadequate product and injector control, has heralded a concerning increase in filler complications. The 10-point plan has been developed to minimize complications through careful preconsideration of causative factors, categorized as patient, product, and procedure related. Patient-related factors include history, which involves a preprocedural consultation with careful elucidation of skin conditions, systemic disease, medications, and previous cosmetic procedures. Other exclusion criteria include autoimmune diseases and multiple allergies. The temporal proximity of dental or routine medical procedures is discouraged. Insightful patient assessment, with the consideration of ethnicity, gender, and generational needs, is of paramount importance. Specified informed consent is vital due to the concerning increase in vascular complications, which carry the risk for skin compromise and loss of vision. Informed consent should be signed for both adverse events and their treatment. Product-related factors include reversibility, which is a powerful advantage when using hyaluronic acid (HA) products. Complications from nonreversible or minimally degradable products, especially when layered over vital structures, are more difficult to control. Product characteristics such as HA concentration and proprietary cross-linking should be understood in the context of ideal depth, placement, and expected duration. Product layering over late or minimally degradable fillers is discouraged, while layering of HA of over the same brand, or even across brands, seems to be feasible. Procedural factors such as photographic documentation, procedural planning, aseptic ­technique, and anatomical and technical knowledge are of pivotal importance. A final section is dedicated to algorithms and protocols for the management and treatment of complications such as hypersensitivity, vascular events, infection, and late-onset nodules. The 10-point plan is a systematic, effective strategy aimed at reducing the risk of dermal filler complications.


  • Top Cited Papers
    Open Access

    Patient factors influencing dermal filler complications: prevention, assessment, and treatment

    by Koenraad De Boulle, Izolda Heydenrych

    While rare, complications do occur with the esthetic use of dermal fillers. Careful attention to patient factors and technique can do much to avoid these complications, and a well-informed practitioner can mitigate problems when they do occur. Since cosmetic surgery is usually an elective process, requested by the patient, clinical trials are complex to organize and run. For this reason, an international group of practicing physicians in the field of esthetics came together to share knowledge and to try and produce some informed guidance for their colleagues, considering the literature and also pooling their own extensive clinical experience. This manuscript aims to summarize the crucial aspects of patient selection, including absolute contraindications as well as situations that warrant caution, and also covers important considerations for the pre- and posttreatment periods as well as during the procedure itself. Guidance is given on both immediate and long-term management of adverse reactions. The majority of complications are related to accepting patients inappropriate for treatment or issues of sterility, placement, volume, and injection technique. It is clear that esthetic practitioners need an in-depth knowledge of all aspects of treatment with dermal fillers to achieve optimal outcomes for their patients.